Expression of brain derived-neurotrophic factor and granulocyte-colony stimulating factor in the urothelium: relation with voiding function

Seung Mo Yuk1, Ju Hyun Shin2, Ki Hak Song2, Yong Gil Na2, Jae Sung Lim2 and Chong Koo Sul2*

Abstract

Background: We designed this experiment to elucidate the relationship between the expression of brain derived-neurotrophic factor (BDNF), the expression of granulocyte-colony stimulating factor (G-CSF), and the development of overactive bladder (OAB). In our previous study, the urothelium was observed to be more than a simple mechanosensory receptor and was found to be a potential therapeutic target for OAB. Moreover, neuregulin-1 and BDNF were found to be potential new biomarkers of OAB. Here, we investigated the relationship between changes in the voiding pattern and the expression of BDNF and G-CSF in the urothelium and evaluated the effects of 5-hydroxymethyl tolterodine (5-HMT) on rats with bladder outlet obstruction (BOO).

Methods: A total of 100 Sprague–Dawley rats were divided into the following groups: 20 control rats; 40 BOO rats; and 40 BOO rats administered 5-HMT (0.1 mg/kg). After BOO was induced for 4 weeks, the rats were assessed by cystometrography. The changes in BDNF and G-CSF expression were examined in both separated urothelial tissues and in cultured urothelial cells by reverse transcription polymerase chain reaction (RT-PCR).

Results: BOO rats showed increased non-voiding activity [NVA; (number/10 voidings)] and bladder weight and decreased micturition volume (MV), micturition interval (MI), and micturition time (MT) relative to the controls. Moreover, the 5-HMT administration rats showed decreased NVA and bladder weight and increased MV and MI in comparison to the BOO rats. BDNF and G-CSF expression was increased in BOO rats and decreased following 5-HMT administration. In this model, voiding dysfunction developed as a result of BOO. As a therapeutic agent for OAB, the administration of 5-HMT improved the voiding dysfunction.

Conclusions: BDNF and G-CSF might modulate voiding patterns through micturition pathways and might be involved only in the urothelium. Moreover, the expression of both genes in the urothelium might be related to voiding dysfunction in OAB patients. Thus, the urothelium has an important role in the manifestation of voiding symptoms.

Keywords: Bladder, Brain derived-neurotrophic factor, Granulocyte-colony stimulating factor, Overactivity

Background

Overactive bladder (OAB) is a clinical syndrome that is characterized by the presence of urinary urgency, with or without urgency incontinence, and is usually accompanied by daytime frequency and nocturia in the absence of proven infection or other obvious pathologies [1]. Bladder outlet obstruction (BOO) results in changes in bladder structure and function that include detrusor hypertrophy, elevated detrusor contractile pressure, and detrusor instability, which can result in OAB [2]. Prolonged BOO can also influence the occurrence and severity of OAB by increasing the production of nerve growth factors (NGF) and thereby inducing neuronal enlargement [3].

The urothelium has specialized sensory and signaling properties through which it responds to the chemical and physical environment and engages in reciprocal chemical communication with neighboring nerves in the...
bladder wall. The detrusor muscle has traditionally been known for having a significant influence on voiding function. However, the urothelium also plays an important role in this process, as evidenced by the effect of changes in urothelial characteristics on the regulation of voiding function. To elucidate the role of the urothelium in voiding function, we have focused solely on this tissue in the absence of the detrusor muscle. In our previous report, we suggested that urothelial-expressed neuregulin-1 and BDNF are potential new biomarkers of OAB [4]. Based on these findings, we believe that the urothelium is more than a simple mechanosensory receptor and may be a potential therapeutic target for OAB treatment. The present study builds upon the work from our previous study by evaluating the relation between voiding dysfunction and the expression of growth factors.

Previous studies have discovered a significant link between BDNF and OAB [4, 5]; however, little is known about whether a significant relationship exists between G-CSF and OAB. Fesoterodine (Pfizer Central Research, Sandwich, UK) is an antimuscarinic drug approved for the treatment of OAB, and is hydrolyzed by a nonspecific esterase to 5-hydroxymethyl tolterodine (5-HMT) [6]. 5-HMT is the active metabolite and is responsible for the antimuscarinic activity of this drug [6]. Antimuscarinics have been found to act in response to muscarinic receptors on detrusor smooth muscle cells to reduce spontaneous myocyte activity during the storage phase [7], thus eventually decreasing the frequency and intensity of detrusor contractions. Hence, the use of 5-HMT as a therapeutic agent of OAB can be used to confirm the presence of OAB, examine the role of BDNF and G-CSF in OAB, and evaluate changes in the urothelium. Here, we evaluated BDNF and G-CSF expression in a BOO rat model and the effect of 5-HMT on their expression both in the urothelium and in cultured urothelial cells (UCs) to understand the relationship between the expression of BDNF and G-CSF and voiding dysfunction. We aimed to test whether 1) OAB occurrence and treatment are related to the BDNF and G-CSF expression, 2) 5-HMT would affect the expression of growth factors on the urothelium, and 3) the urothelium functions as more than a simple mechanosensory receptor in regulating bladder functions.

Methods

Animals

Female Sprague–Dawley rats (250–300 g; Daehan Biolink Co. Ltd, Daejeon, Korea) were used in this study. The experimental protocol was approved by the Animal Ethics Committee of the University of Chungnam, South Korea. The rats were handled according to the NIH guidelines. The sample size needed for evaluating the expression of the different growth factors, as affected by BOO, was determined. To achieve a power of 0.8, alpha value of 0.05, and sample size rate of 2 for detecting statistical differences, 11 animals would be required as controls.

Group I (20 rats) was the control group, group II (40) comprised BOO rats, and group III (40) comprised BOO rats injected with 5-HMT (0.1 mg/kg) in the rat tail vein (2 times/weeks) for 3 weeks. These doses of 5-HMT generally correspond to the doses used clinically in humans [8]; the 5-HMT was generously provided by Pfizer. The BOO rats were injected with 5-HMT as described by Melman et al. [9]. For inducing BOO, a lower midline incision was made to approach the bladder of each anesthetized rat and to expose the proximal urethra. A 3–0 polypropylene suture was used to tie the proximal urethra with a 24-G angioneedle sheath. After suturing, the angioneedle sheath was removed, leaving the urethra partially obstructed.

Cystometry investigations

The BOO rats were anesthetized 4 weeks after they were injected with 5-HMT. Polyethylene catheters were implanted through the bladder dome and exteriorized at the scapular level. A cystometry procedure was performed in conscious rats 4 days after catheter implantation. A tube was connected to a pressure transducer (Powerlab, ADInstrument, Sydney, NSW, Australia) and an infusion pump (Promed-Tech., Bellingham, Massachusetts, USA) via a 3-way stopcock to record intravesical pressure (IVP) and to infuse saline into the bladder, respectively. Micturition volumes (MV) were recorded with a fluid collector connected to a force displacement transducer (Grass Inst. Co., Quincy, MA, USA). Room-temperature saline was infused into the bladder continuously at a rate of 0.2 ml/min. After the voiding pattern stabilized, the micturition cycles were recorded. The IVP and MV were recorded continuously with a data acquisition system (Chart software v5.5.6, ADInstrument) at a sampling rate of 2000 Hz.

In addition to MV, the following parameters were analyzed based on the cystometry results: micturition pressure (MP, maximum bladder pressure during micturition), basal pressure (BP, minimum bladder pressure between two micturitions), micturition interval (MI), micturition time (MT), and bladder weight (Fig. 1). Pressure values were compared by calculating the difference between BP values.

Tissue preparation

After cystometry, the bladder of each rat was excised at the level of the ureteric orifices and proximal urethral and subsequently weighed. The urothelium and detrusor muscles were separated under microscopic vision with microscissors and microforceps. The separated layers from half of the bladder were stored in liquid nitrogen.
for reverse transcription polymerase chain reaction (RT-PCR) until needed. The other half of the bladder was used as soon as possible for primary cell cultures.

RT-PCR of urothelium-expressed RNA
Total RNA was extracted from the frozen urothelium using Trizol (Invitrogen, Carlsbad, CA, USA). One milliliter of Trizol was added to the urothelium and homogenized in a 5-ml glass tube. The homogenate was transferred to a 1.0-ml tube and was mixed with 0.2 ml of 99 % chloroform (Sigma-Aldrich, St. Louis, MO, USA). After incubation for 5 minutes at room temperature, the homogenate was centrifuged at 13,200 × g for 10 minutes at room temperature. The supernatant was transferred to a clean tube, and 1 ml of isopropyl alcohol (Sigma-Aldrich) was added, followed by further centrifugation. After the supernatant was discarded, the pellet was mixed with 0.5 ml of diethylpyrocarbonate (DEPC; Sigma-Aldrich) and centrifuged at 13,200 × g for 10 minutes at room temperature. After discarding the

Fig. 1 Representative cystometry results for the different study groups. Representative tracing of the cystometry parameters for intravesical pressure (IVP; cmH2O) and micturition volume (MV; ml). Black arrows represent non-voiding activity (NVA). A. Group I (controls). B. Group II (BOO rats). C. Group III (BOO rats administered 5-HMT).
supernatant, the pellet was dried at room temperature, dissolved with DEPC-treated water, and stored at −75 °C. cDNA was then prepared from 1 μg of random priming by using a First-Strand cDNA synthesis kit (Enzymonics, Korea), in accordance with the manufacturer’s protocol. It was incubated at 50 °C for 50 minutes, 70 °C for 10 minutes, and finally stored at −20 °C. The primer pair sequences are listed in Table 1. GAPDH was used as the reference gene. After an initial denaturation step at 95 °C for 5 min, an annealing procedure of 35 cycles (58 °C for 30 s), and an extension step (72 °C for 30 s and 72 °C for 5 min), were performed. The PCR products were separated on 1.2 % ethidium-containing agarose gels and photographed under an ultraviolet transilluminator. The band intensities were quantified by densitometry and qualified by Bio-ID (Vilber Lourmat, France).

Urothelial cell culture
UCs were harvested from the bladders of each group using a previously described trypsin-based method (Gibco, Invitrogen, Carlsbad, CA, USA). The bladder was removed and placed in cold minimal essential medium (MEM; Invitrogen, Carlsbad, CA) supplemented with HEPES (2.5 g/l, Sigma, St. Louis, MO) and containing 1 % penicillin/streptomycin/fungi zone (PSF; Sigma). The bladder was turned inside out and incubated in dispase (2.5 mg/ml; Worthington Biochemical, Lakewood, NJ) overnight at 4 °C. UCs were gently scraped from the underlying tissue, placed in trypsin (0.25 % wt/vol; Sigma) for 10–15 min at 37 °C, and dissociated by trituration. Cells were suspended in MEM containing 10 % FBS (Invitrogen) and centrifuged at 416 g × g for 10 min. After the supernatant was removed, the cells were suspended in keratinocyte medium (bovine pituitary extract: 60 g/ml, hydrocortisone: 0.5 g/ml, insulin: 5 g/ml, epidermal growth factor: 0.1 ng/ml, gentamicin: 50 g/ml, amphotericin [Bio Whittaker, Walkersville, Maryland]: 15 ng/ml, and human recombinant cholera toxin [Calbiochem, San Diego, California]: 8.3 ng/ml, 2 % FBS [Invitrogen]) with 1 % PSF, centrifuged again, and resuspended in fresh media. Cells were plated on collagen-coated glass coverslips at densities of 50–70 × 10^4 cells/ml. Media was added after 4 hours of incubation at 37 °C following cell isolation and changed every other day. Cultured UCs were analyzed 48 hours after dissociation.

RT-PCR of primary cultured UCs
RNA was prepared using the Cells-to-cDNA II kit (Ambion Europe Ltd, Huntingdon, UK). The lysates of the cell layer were processed according to the instructions until just before the RT step (i.e., 75 °C for 10 minutes, DNase I digestion at 37 °C for 15 minutes, and 75 °C for 5 minutes). The RNA preparations were stored at −20 °C for a short period. RT was also performed using the kit, according to the instructions using the random decamers provided as well as 5 μl of cell lysate (RNA). The resultant cDNA was diluted 5 times with water and stored at −20 °C. PCR was conducted using primer sets in accordance with the above-described method (Table 1).

Data analysis
All statistical analysis was performed using SPSS, version 20.0 for windows (SPSS Inc., Chicago, IL, USA). A non-parametric Kruskal-Wallis test followed by a post-hoc test (Scheffe’s multiple comparison test) were performed for comparisons between the 3 groups. Differences were considered statistically significant when P < 0.05. The results are expressed as the mean ± sd.

Results
Animals
One hundred rats were used in the study: group I (20 rats), group II (40 rats), and group III (40 rats). Two rats each died in groups II and III after the BOO procedure. All control groups had a sham operation, and the cystometric investigations were performed after 4 weeks. Two rats in group II and 3 rats in group III were excluded because of failed BOO (i.e., no change in bladder weight and no difference in the voiding pattern compared to the control group). In the final analysis, groups I, II, and III had 20, 36, and 35 rats, respectively.

Cystometry
Group II rats showed increased non-voiding activity [NVA; (number/10 voidings)] and bladder weight and decreased MV, MI, and MT relative to the control group (Table 2). Group III rats showed reduced NVA and bladder weight and increased MV and MI in comparison to group II rats.

RT-PCR results for the urothelium
Group II showed the highest expression of BDNF in the urothelium in comparison to groups I and III. G-CSF expression was significantly higher in group II relative to groups I and III, but did not significantly differ between

---

Table 1 List of primer sequences used for RT-PCR

| Gene   | Primer sequence        | Product |
|--------|------------------------|---------|
| GAPDH  | Forward: CAC GGC AAG TTC AAC GGC AC | 189 bp  |
|        | Reverse: AGC GGA AGG GCC GGA GAT GA |         |
| BDNF   | Forward: CAT TCT TTC CCT CCC TCC TC | 360 bp  |
|        | Reverse: CAG CTC CAC TTA GCC TCC AC |         |
| G-CSF  | Forward: TTG GCC ACT CTC TGG GTA TC | 348 bp  |
|        | Reverse: GGT GAG CTG TCT CCA GGA AG |         |
groups I and III (Fig. 2). The injection of 5-HMT injection suppressed and partially suppressed the up-regulated mRNA expression of BDNF and G-CSF in BOO rats, respectively. Therefore, the changes in the voiding patterns were related to the expression of BDNF and G-CSF in the urothelium.

Culturing and RT-PCR of UCs
In culture, the UCs proliferated and formed small islands (5–30 cells/island) (Fig. 3). No significant differences were observed in the number of living UCs between groups, indicating that no problems had resulted from the cell harvesting and culturing methods. The results for the cultured UCs were similar to those of the urothelium. The expression of BDNF and G-CSF was upregulated in the UCs of group II compared to that in the control, but was downregulated in group III (Fig. 4). The changes in both growth factors were related to the changes in the voiding patterns.

Discussion
The changes in urothelial BDNF and G-CSF have not been previously observed in other OAB models. This might be due to the fact that neurogenic or myogenic BOO was assessed in these previous studies. This is an experimental model where, in particular, the BOO is "quickly" made instead of clinical OAB-BOO. Detrusor overactivity (DO) is the urodynamic hallmark of OAB, and the BOO rat can be useful for assessing potential pharmacotherapeutic concepts of DO in humans [11]. Moreover, various voiding patterns following BOO have been reported in this model. DO was identified and recorded as non-micturition-related increases in IVP [12], and a significant increase in MP was observed with this condition [2]. The common result of DO is a markedly shortened MI. The NVA in the present cystometry data consisted of small phasic contractions in the filling bladder. NVA is believed to represent the motor component of a motor/sensory system [13-15] and is accentuated in BOO. Moreover, NVA shows characteristics similar to DO in patients with OAB. Furthermore, t olterodine has been shown to significantly decrease the number and amplitude of NVA [16, 17]. In line with the cystometry results, the voiding pattern of groups II and III had characteristics similar to those for OAB and the treated condition. Hence, the present model is suitable as an experimental model.

In the storage phase, mechanical stretch stimulates the bladder afferents. This mechanosensory information is constantly sent to the central nervous system [18]. Alterations in afferent activity may lead to lower urinary tract dysfunction and is one of the possible mechanisms for OAB [18]. As the urothelium is a mechanosensory receptor, bladder function is influenced according to the changing state of the urothelium. Growth factors also may play a role in bladder function. Moreover, growth

---

**Table 2** Comparison of cystometric parameters and bladder weight between the experimental groups. The results of various cystometric parameters and bladder weight for group I (control), group II (BOO rats), and group III (BOO rats after 5-HMT administration) are shown

| Group (n) | TP-BP | BP-BP | MV  | MI  | MT  | NVA | Bladder weight |
|-----------|-------|-------|-----|-----|-----|-----|---------------|
| I (20)    | 14.0 (a) ±0.97 | 55.4 (a) ±4.64 | 0.61 (a) ±0.06 | 64.7 (a) ±4.36 | 11.6 (a) ±1.33 | 0.15 (a) ±0.37 | 116.5 (a) ±8.26 |
| II (26)   | 9.5 (b) ±6.95 | 55.2 (a) ±8.31 | 0.19 (b) ±0.05 | 27.4 (b) ±4.26 | 10.6 (b) ±0.85 | 2.36 (b) ±0.49 | 212.1 (b) ±12.00 |
| III (25)  | 4.9 (c) ±3.51 | 49.2 (b) ±4.65 | 0.27 (c) ±0.64 | 39.3 (c) ±5.91 | 10.7 (b) ±1.45 | 1.31 (c) ±0.47 | 197.4 (c) ±10.66 |

p-value: 1) 0.000 0.001 0.000 0.000 0.017 0.000 0.000

TP, BP, MP: cmH2O; MV: mL; MT: seconds; bladder weight: mg; NVA (number/10 voidings)
The same letters indicate non-significant differences between groups based on Scheffe’s multiple comparison tests

1) Statistical significance among the different groups was tested by a nonparametric Kruskal-Wallis test

---

**Fig. 2** RT-PCR expression of BDNF and G-CSF in the urothelium. A. RT-PCR results. B. Densitometry measurements. *indicates statistical significance between groups (p < 0.001) as tested by a nonparametric Kruskal-Wallis test. The same letters indicate non-significant differences between groups based on Scheffe’s multiple comparison tests
factors have been found to play a crucial role in various cellular processes such as proliferation, differentiation, migration, apoptosis, and neurodegeneration [19]. Previous research has examined the correlation between OAB and NGF. It was observed that increased NGF expression in the bladder may contribute to storage symptoms (e.g., urgency and frequency) in patients with OAB [20, 21]. In addition, NGF expression in the bladder was found to be associated with the clinical symptoms of OAB [22]. It has become clear that NGF modulates neuronal function along micturition pathways, is involved in multiple bladder pathologies, and serves as a urinary marker of OAB [21]. BDNF, a member of the NGF family, is primarily present in the sensory neuronal cell body in the dorsal root ganglion and is involved in sensory neuronal activation in a variety of animal models [23]. Of note, BDNF synthesis has been shown to be stronger in the bladder after chronic bladder inflammation [5]. Moreover, in patients with bladder pain syndrome/interstitial cystitis, the urinary concentration of BDNF was high at baseline but was significantly reduced after botulinum toxin administration to the bladder trigone [24]. Consistent with this previous finding, BDNF sequestration improved voiding function in rats with chronic cystitis [5]. Accordingly, BDNF has been found to be a sensitive indicator of the resolution of lower urinary tract disorders by therapeutic management [4].

On the other hand, the G-CSF receptor is markedly upregulated in neurons during cerebral ischemia and has direct effects on neurons, including the reduction of neuronal apoptosis and the stimulation of endogenous neural progenitors [25]. A further mechanism of action for G-CSF in stroke is the mobilization of bone marrow-derived stem cells to participate in neurogenesis and angiogenesis [26]. G-CSF has also been shown to have neuroprotective effects after peripheral axotomy [27]. Previous studies have also investigated G-CSF in terms of the diagnosis and treatment of bladder cancer. However, no prior research has confirmed the relevance of G-CSF to voiding function. In the present study, the functions of G-CSF and BDNF in the urothelium were evaluated at the tissue and cellular level by specifically using only the urothelium and UCs. A similar upregulation of G-CSF and BDNF expression and subsequent downregulation following 5-HMT treatment was observed in BOO rats for both the urothelium and UCs. BOO has been found to induce inflammation, multiple nerve injury, and changes in nerve density [28]. One
effect stemming from neural damage inflicted by BOO might be an increase in the neuroprotective activity of G-CSF. Nonetheless, a clear mechanism, in terms of changes in the expression of these growth factors and their attendant roles, remains unknown.

DO might be attributable to an increase in afferent activation. The proximity of the afferent nerves to the urothelium suggests that chemicals released by the urothelium might alter afferent excitability. Hence, the urothelium could be important in the manifestation of voiding symptoms, and changes in the expression of various urothelial receptors might play a key pathophysiological role in OAB occurrence. At therapeutic doses, muscarinic antagonists do not seem to inhibit bladder contractility [29]. Hence, OAB appears to be affected by factors other than those involved in bladder muscle contractile dysfunction, thus also suggesting that the urothelium potentially plays an important role in voiding function. Based on these findings and additional previous ones, the investigation of urothelium-expressed G-CSF and BDNF in voiding function seemed suitable for further exploring urothelial function. In particular, previous studies have indicated that NGF, BDNF, prostaglandins, cytokines, and C-reactive protein may be suitable biomarkers of OAB [4, 30-32]. Furthermore, the evaluation of urine samples from OAB patients revealed that G-CSF is upregulated by several different molecules [33]. Within the present experimental context, the use of the urothelium and cultured UCs from the bladder allowed a more robust examination of the changes in these growth factors. In both rats and humans, the M1 to M5 muscarinic receptors are distributed throughout the urothelium [34], and Kullmann et al. detected the expression of all 5 muscarinic receptors subtypes in UCs [35]. We chose 5-HMT as a non-selective agent that could serve as a competitive blocking agent for all muscarinic receptors [6, 36]. Following 5-HMT administration, both growth factors were altered in the control as voiding dysfunction improved. Because the changes in the growth factors were observed in the urothelium and UCs, they will also presumably affect bladder function. Hence, based on the present findings, the urothelium may not only function simply as a mechanosensory receptor, but also play an important role in bladder function. Our study also provides new evidence that 5-HMT has a significant effect on the expression of growth factors in addition to its antimuscarinic tendencies.

A limitation of the present study is that quantitative tests could not be performed because of the small number of UCs. However, the use of RT-PCR with the cell culture allowed an examination of the changes in the characteristics of the UCs. The results showed that BDNF and G-CSF expression was altered in each group and that these alterations had a significant relationship with voiding function.

Conclusions
BNDF and G-CSF expressions were increased in BOO rats and decreased following 5-HMT administration in both the urothelium and UCs. The expression of BDNF and G-CSF in the urothelium might be related to voiding dysfunction in OAB patients. As a therapeutic agent for OAB, 5-HMT improves voiding dysfunction. Based on the present findings, the urothelium plays an important role in the manifestation of voiding symptoms.

Abbreviations
5-HMT: 5-Hydroxymethyl tolterodine; BP: Basal pressure; BOO: Bladder outlet obstruction; BDNF: Brain-derived neurotrophic factor; UCs: Cultured urothelial cells; G-CSF: Granulocyte-colony stimulating factor; NP: Intravesical pressure; MEM: Minimal essential medium; M: Micturition interval; MP: Micturition pressure; MT: Micturition time; MV: Micturition volume; NGF: Nerve growth factor; NVA: Non-voiding activity; OAB: Overactive bladder; RT-PCR: Reverse transcription polymerase chain reaction.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
SMY conceived of the study, participated in its design and coordination, carried out the cystometry, performed the statistical analysis, and helped draft and critically revise the manuscript. JHS conducted the immunoassays and participated in the design of the study. KHS, YGN, and JSL participated in the design of the study, performed the statistical analysis, and helped draft and critically revise the manuscript. CKS conceived of the study, in the design of the study, performed the statistical analysis, and helped draft and critically revise the manuscript. All authors read and approved the final manuscript.

Acknowledgements
The funding source had no role in the design, in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication.

Author details
1Department of Urology, Korea St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea. 2Department of Urology, Korea Chungnam National University Hospital, College of Medicine, Chungnam National University, Daejeon, South Korea.

Received: 6 January 2015 Accepted: 30 April 2015
Published online: 08 May 2015

References
1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier R, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–88.
2. Kim JC, Yoo JS, Park EY, Hong SH, Il Seo S, Hwang TK. Muscarinic and purinergic receptor expression in the urothelium of rats with detrusor overactivity induced by bladder outlet obstruction. BJU Int. 2008;101(3):371–5.
3. Steers WD, De Groat WC. Effect of bladder outlet obstruction on micturition reflex pathways in the rat. J Urol. 1988;140(4):864–71.
4. Fry CH, Sahai A, Vahabi B, Kanai AJ, Birder LA. What is the role for biomarkers for lower urinary tract disorders? JO-RS 2013. Neurourol Urodyn. 2014;33(5):602–5.
5. Pinto R, Fria B, Allen S, Dawbarn D, McMahon SB, Cruz F, et al. Sequestration of brain derived nerve factor by intravesical delivery of TrkB-Ig2 reduces bladder overactivity and noxious input in animals with chronic cystitis. Neuroscience. 2010;166(3):907–16.
6. Michel MC. Fetoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother. 2008;9(10):1787–96.
7. Andersson KE. Storage and voiding symptoms: pathophysiologic aspects. Urology. 2003;62(5 Suppl 2):3–10.
8. Fullhase C, Soler R, Gratze C, Brodsky M, Christ GJ, Andersson KE. Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction. BJU Int. 2010;106(2):287–93.

9. Melman A, Tar M, Boczkó J, Christ G, Leung AC, Zhao W, et al. Evaluation of two techniques of partial urethral obstruction in the male rat model of bladder outlet obstruction. Urology. 2005;66(3):1127–33.

10. Kurzrock EA, Lieu DK, de Graffenried LA, Isseroff RR. Rat urothelium: improved techniques for serial cultivation, expansion, freezing and reconstitution onto acellular matrix. J Urol. 2005;173(1):281–5.

11. Lluel P, Duquenne C, Martin D. Experimental bladder instability following bladder outlet obstruction in the female rat. J Urol. 1998;160(6 Pt 1):2253–7.

12. Lee T, Andersson KE, Streng T, Hedlund P. Simultaneous registration of intraabdominal and intravesical pressures during cystometry in conscious rats: effects of bladder outlet obstruction and intravesical PGE2. NeurourolUrodyn. 2008;27(1):88–95.

13. Streng T, Hedlund P, Talo A, Andersson KE, Gillespie JI. Phasic non-micturition contractions in the bladder of the anaesthetized and awake rat. BJU Int. 2006;97(10):1094–101.

14. Gillespie JI. The autonomous bladder: a view of the origin of bladder overactivity and sensory urge. BJU Int. 2004;93(4):747–51.

15. Gillespie JI, van Koeveringe GA, de Wachter SG, de Vente J. On the origins of the sensory output from the bladder: the concept of afferent noise. BJU Int. 2009;103(10):1524–33.

16. Gillespie JI, Palea S, Guilloteau V, Guerard M, Lluel P, Korstanje C. Modulation of non-voiding activity by the muscarinic agonist tolterodine and the beta(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction. BJU Int. 2012;110(2 Pt 2):E132–42.

17. Kailo Y, Nishiguchi J, Kwon DD, Chancellor MB, Arai Y, Snyder PB, et al. The effects of a type 4 phosphodiesterase inhibitor and the muscarinic cholinergic agonist tolterodine tartrate on detrusor overactivity in female rats with bladder outlet obstruction. BJU Int. 2008;101(5):615–20.

18. Yoshimura N. Bladder afferent pathway and spinal cord injury: possible mechanisms inducing hyperreflexia of the urinary bladder. Prog Neurobiol. 1999;57(6):583–606.

19. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773(8):1263–84.

20. Lawe EM, Anand P, Terenghi G, Williams-Chestnutt RE, Sincirovic DV, Osborne JL. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Urol. 1997;79(4):572–7.

21. Steers WD, Tuttle JB. Mechanisms of Disease: the role of nerve growth factor in the pathophysiology of bladder disorders. Nat Clin Pract Urol. 2006;3(2):101–10.

22. Kim JC, Park EY, Seo SI, Park YH, Hwang TK. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol. 2006;175(5):1773–6; discussion 1776.

23. Tao X, Finkbeiner S, Arnold DB, Greenberg ME. Ca(2+) influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron. 1999;20(4):709.

24. Zarghooni S, Wunsch J, Bodenbenner M, Bruggmann D, Giando SA, Schwantes U, et al. Expression of muscarinic and nicotinic acetylcholine receptors in the mouse urothelium. Life Sci. 2007;80(24–25):2338–13.

25. Kullmann FA, Artim D, Beckel J, Barrick S, de Groat WC, Bird LA. Heterogeneity of muscarinic receptor-mediated Ca(2+) responses in cultured urothelial cells from rat. Am J Physiol Renal Physiol. 2008;294(4):F971–81.

26. Ney P, Pandita RK, Greenstreet DT, Breidenbach A, Stohr T, Andersson KE. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int. 2008;101(8):1036–42.

27. Finney SM, Andersson KE, Gillespie JI, Stewart LH. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int. 2006;98(3):503–7.

28. Bhide AA, Cartwright R, Khullar V, Digesu GA. Biomarkers in overactive bladder. Int Urogynecol J. 2013;24(7):1085–72.

29. Antunes-Lopes T, Carvalho-Barros S, Cruz CD, Cruz F, Martins-Silva C. Biomarkers in overactive bladder: a new objective and noninvasive tool? Adv Urol. 2011;2011:382431.

30. Wang LW, Han XM, Chen CH, Ma Y, Hai B. Urinary brain-derived neurotrophic factor: a potential biomarker for objective diagnosis of overactive bladder. Int Urol Nephrol. 2014;46(2):341–7.

31. Ghoniem G, Fanuq N, Elmirissy M, Mady A, Abdelwalah H, Oommen M, et al. Differential profile analysis of urinary cytokines in patients with overactive bladder. Int Urogynecol J. 2011;22(8):953–61.

32. Zarghooni S, Wunsch J, Bodenbenner M, Bruggmann D, Giando SA, Schwantes U, et al. Expression of muscarinic and nicotinic acetylcholine receptors in the mouse urothelium. Life Sci. 2007;80(24–25):2338–13.

33. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773(8):1263–84.

34. Pinto R, Lopes T, Frias B, Silva A, Silva JA, Silva CM, et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol. 2010;58(3):360–5.

35. Schneider A, Kruger C, Steigleder T, Weber D, Pitzer C, Laage R, et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Investig. 2005;115(8):2083–98.

36. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cerullo M, et al. Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades. Oncotarget. 2012;3(9):954–87.